Quick Overview
- Eli Lilly revealed its intention to purchase three vaccine development companies — Curevo, LimmaTech Biologics, and the Vaccine Company — for a total approaching $4 billion.
- The Curevo acquisition carries a valuation of up to $1.5 billion, with the company developing a shingles vaccine targeting adult populations.
- LimmaTech specializes in vaccines combating bacterial infections including sexually transmitted diseases, with a deal valued at up to $780 million.
- The Vaccine Company’s acquisition, valued at up to $1.55 billion, centers on developing a vaccine for the Epstein-Barr virus.
- Shares of LLY climbed approximately 1.3% to 1.6% during premarket hours following the announcement.
Eli Lilly is committing close to $4 billion to establish a foothold in infectious disease prevention. On Tuesday, the pharmaceutical giant revealed agreements to purchase three biotechnology companies: Curevo, LimmaTech Biologics, and the Vaccine Company.
Shares of LLY experienced gains between 1.3% and 1.6% during premarket trading following the disclosure.
The three transactions are configured with initial payments alongside contingent milestone-based payments dependent on clinical development and commercialization achievements. The aggregate value reaches approximately $3.83 billion.
This strategic pivot represents a significant departure for the pharmaceutical company renowned for its successful GLP-1 medications. Daniel Skovronsky, Lilly’s chief scientific and product officer, articulated the rationale clearly: “These acquisitions reflect a deliberate strategy to prevent disease at its source rather than treat its consequences.”
Curevo represents the most substantial transaction at up to $1.5 billion. The company has created a shingles vaccine utilizing a synthetic adjuvant — formulated to enhance immune system response while minimizing adverse effects relative to currently available alternatives.
The Vaccine Company follows closely with a valuation reaching $1.55 billion. The firm is advancing In Vivo Nanoparticle technology aimed at viral pathogen elimination, with primary emphasis on the Epstein-Barr virus — a widespread infection lacking any approved vaccine currently available.
LimmaTech completes the acquisition trio valued at up to $780 million. The company’s development pipeline addresses bacterial pathogens, particularly Neisseria gonorrhoeae and chlamydia trachomatis — organisms demonstrating increasing antibiotic resistance and creating significant treatment challenges.
GLP-1 Revenue Powers Expansion
Lilly’s buying initiative is financed through extraordinary revenues generated by its diabetes and weight-loss medications. During the first quarter, Zepbound produced $4.16 billion in U.S. revenue, while Mounjaro contributed $4.2 billion.
This financial strength has provided Lilly the flexibility to diversify significantly beyond its weight-management portfolio. The three vaccine acquisitions continue Lilly’s trend of allocating capital toward novel therapeutic categories while expanding its development pipeline.
The pharmaceutical company currently commands a 60.1% market share in the U.S. obesity medication sector, with competitor Novo Nordisk holding 39.4%. Lilly also recently introduced Foundayo, its newly authorized oral GLP-1 obesity medication, during the second quarter.
Targeting Unmet Medical Needs
Each acquisition addresses a specific area where approved vaccines remain unavailable or where significant improvement opportunities exist.
Shingles impacts approximately one-third of Americans during their lifetime. The Epstein-Barr virus infects roughly 90% of the global adult population and has demonstrated associations with specific cancers and multiple sclerosis. Bacterial sexually transmitted infections such as gonorrhea are experiencing escalating resistance to current antibiotic therapies.
Lilly has not revealed the precise upfront payment figures for any of the three transactions, disclosing only the combined potential transaction values that include milestone payments.
The Wall Street Journal initially disclosed the acquisitions Tuesday morning prior to Lilly’s formal public statement.
Get 3 Free Stock Ebooks
Discover top-performing stocks in AI, Crypto, and Technology with expert analysis.
- Top 10 AI Stocks - Leading AI companies
- Top 10 Crypto Stocks - Blockchain leaders
- Top 10 Tech Stocks - Tech giants
